Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 21:10:4135-4141.
doi: 10.2147/OTT.S136569. eCollection 2017.

Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma

Hisashi Saji  1   2 , Hiroki Sakai  1 , Hiroyuki Kimura  1 , Tomoyuki Miyazawa  1 , Hideki Marushima  1 , Haruhiko Nakamura  1
Affiliations

Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma

Hisashi Saji et al. Onco Targets Ther. .

Abstract

Objective: We previously reported that the staging system and epidermal growth factor receptor (EGFR) mutation status are key factors for treatment strategy and predicting survival. However, the significance of these factors as predictors of overall survival (OS) and postoperative recurrence survival (PRS) has not been sufficiently elucidated. The objective here was to investigate EGFR mutation status and p-stage, which affect PRS and OS in patients with completely resected lung adenocarcinoma, using a different database.

Patients and methods: We retrospectively reviewed 56 consecutive lung adenocarcinoma patients with disease recurrence in St. Marianna University Hospital between January 2010 and December 2014.

Results: EGFR mutants (M) were detected in 16/56 patients (29%). The patients with EGFR M had a better OS than those with EGFR wild-type (WT) status (5-year survival: 50.3% vs 43.1, P=0.133). There was no significant difference in the 3-year recurrence-free survival rate between patients with M and WT (6.3% vs 7.7%, P=0.656), and the patients with EGFR M had a significantly better 3-year PRS than those with WT (77.4% vs 51.7%, P=0.033). The 3-year PRS rate for patients with M/pathologic stage (p-stage) I-II (87.5%) was better than that for patients with M/p-stage III (60.0%), WT/p-stage I-II (52.7%), and WT/p-stage III (43.8%). There was a significant difference between patients with M/p-stage I and WT/p-stage I-II or WT/p-stage III (P=0.021 and 0.030, respectively). During the study period, of the 16 patients with mutants, 12 patients (75%) received EGFR-tyrosine kinase inhibitor (TKI) therapy and among the 40 patients with WT, no patient received EGFR-TKI therapy. Multivariate survival analysis showed that patients with EGFR-TKI therapy had a statistically significant association with favorable PRS (hazard ratio 0.271; 95% confidence interval 0.074-1.000; P=0.050).

Conclusion: EGFR status and p-stage were found to be essential prognostic factors for estimating PRS using this database. The recurrent patients with EGFR M and EGFR-TKI therapy had a statistically significant association with favorable PRS.

Keywords: EGFR; lung adenocarcinoma; postoperative recurrence survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
(A) Overall survival stratified according to EGFR mutants and WT. (B) RFS stratified according to EGFR mutants and WT. (C) PRS stratified according to EGFR mutants and WT. Significant differences in the PRS rates were observed between the patients with mutants and WT (P=0.030). (D) PRS stratified according to EGFR status and p-stage. Significant differences in the PRS rates were observed between the patients with mutants/p-stage I–II and WT/p-stage I–II (P=0.030) and between the patients with mutants/p-stage I–II and WT/p-stage III (P=0.021). Abbreviations: EGFR, epidermal growth factor receptor; PRS, postoperative recurrence survival; p-stage, pathologic stage; RFS, recurrence-free survival; WT, wild type.
Figure 2
Figure 2
(A) Overall survival stratified according to whether EGFR-TKIs were administered or not. (B) RFS stratified according to whether EGFR-TKIs were administered or not. Significant differences in the PRS rates were observed between the patients with and without EGFR-TKIs (P=0.045). Abbreviations: EGFR, epidermal growth factor receptor; PRS, postoperative recurrence survival; RFS, recurrence-free survival; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

References

    1. Yoshino I, Yohena T, Kitajima M, et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 2001;7(4):204–209. - PubMed
    1. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax. 2009;64(3):192–196. - PubMed
    1. Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010;65(3):241–245. - PubMed
    1. Shimada Y, Saji H, Yoshida K, et al. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. Chest. 2013;143(6):1626–1634. - PubMed
    1. Kudo Y, Shimada Y, Saji H, et al. Prognostic factors for survival after recurrence in patients with completely resected lung adenocarcinoma: important roles of epidermal growth factor receptor mutation status and the current staging system. Clin Lung Cancer. 2015;16(6):e213–e221. - PubMed